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Background: As a rare tumor, yolk sac tumor is a type of neoplasm that appears like the yolk sac, extraembryonic mesenchyme, 
and allantois. The mediastinum is the second most frequent area after the gonadal area. Case report: We present an extremely rare 
case of 15 years old boy with mediastinal yolk sac tumor. The boy came with the chief complaint of swelling of the neck and face. 
Computed tomography scan of the chest revealed bulky mass with a cystic component that infiltrated the heart. The diagnosis 
of mediastinal yolk sac tumor was made after core needle biopsy. Histopathologic analysis revealed tumor mass with solid and 
microcystic structure and pleomorphic nucleus within the tumor cells. Laboratory finding showed elevated serum alpha-fetoprotein 
level reaching more than 8000 ng/ml. Echocardiography revealed a mass in the right atrium. The patient condition was rapidly 
deteriorated due to his vena cava superior syndrome. Unfortunately, the patient died two days after diagnosis and we did not have 
the chance to do the therapy. Conclusion: Mediastinal yolk sac tumor is a rare malignancy that requires comprehensive manage-
ment. The diagnosis should be made based on histopathological findings with the addition of thoracic computer tomography scan 
to assess the degree of infiltration to surrounding organ. A life-threatening condition such as vena cava superior syndrome should 
be assessed promptly to allow for immediate treatment.
Key Words: mediastinal yolk sac tumor, heart infiltration.
Germ cell tumors (GCTs) are rare tumors that arise 
from primordial germ cells [1]. The incidence of GCTs 
can be estimated at 0.9 per 100,000 children. In young 
men, malignant GCTs are the most common malignant 
tumor entity with an incidence of 7–8 per 100,000 per-
sons [2]. GCTs are usually located in gonadal sites 
(testis, ovarium). However, 1–5% GCTs are of ex-
tragonadal origin with the most common primary site 
in the anterior mediastinum (50–70%), followed by the 
retroperitoneal cavity, pineal gland, sacrococcygeal 
region, and vagina [2–5]. GCTs, regardless the site 
of the tumors, are classified into two categories: semi-
noma and nonseminomatous GCTs. Yolk sac tumor 
is nonseminomatous malignant GCTs that resembles 
yolk sac and extraembryonic mesenchyme [6]. Me-
diastinal yolk sac tumor is a malignant GCT which has 
a poor prognosis despite modern chemotherapy [5, 
7]. In this report, we present a rare case of mediastinal 
yolk sac tumor in 15 years old boy that infiltrated the 
heart and formed a mass in the right atrium.
CASE REpORT
Fifteen years old boy came with his parents to our 
outpatient clinic with a chief complaint of swelling 
of his face and neck. The patient was admitted 
to regional hospital for one week due to progres-
sive dyspnea and referred to our hospital for further 
diagnosis and treatment. The patient presented with 
a cough with whitish sputum, history of hemoptysis, 
loss of weights, and dysphagia. The physical exami-
nation revealed tachycardia, increased respiratory 
rate, isolated edema of the face and neck, elevated 
jugular venous pressure, the dull percussion of the 
left chest and decreased breath sound on the left 
lung.
The chest x-ray showed homogeneous consoli-
dation covering the left hemithorax that pushed the 
heart to the right. Computed tomography scan of the 
chest showed a bulky mass with a cystic component 
in the anterior mediastinum predominantly on the left 
hemithorax measuring 15 × 12 cm in the axial plane and 
15.2 × 15 cm on the coronal plane (Fig. 1). This mass 
extended to the right hemithorax and compressed 
superior vena cava. The mass also infiltrated to the 
right atrium. The beta-human chorionic gonadotropin 
level was within the normal limit but the serum alpha-
fetoprotein level was elevated to > 8000 ng/ml. The 
electrocardiogram (ECG) revealed low QRS voltage 
suggestive of pericardial effusion. Echocardiography 
revealed a mass in the right atrium, pericardial effu-
sion, with mild tricuspid regurgitation and mitral regur-
gitation (Fig. 2). Core needle biopsy was performed 
and diagnosis of mediastinal yolk sac tumor was 
made based on the histopathological finding. On the 
histopathologic examination, we found tumor mass 
with solid and microcystic structure. The tumor cells 
appeared to have polymorphic nuclei. We didn’t find 
Schiller — Duval body which is pathognomonic for yolk 
sac tumors (Fig. 3).
Fig. 1. Chest computed tomography showing a mass in the 
anterior of the mediastinum and infiltrate the right atrium
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Fig. 2. Echocardiography revealed a mass in the right atrium
Fig. 3. Histopathologic examination showed tumor mass with 
solid and microcystic structure. The tumor cells have a pleomor-
phic nucleus, x 200
Due to the superior vena cava syndrome, we per-
formed elevation of the head and neck, administered 
supplemental oxygen, intravenous corticosteroid, and 
performed five fraction of radiotherapy (total of 1500 cGy) 
to the tumor location. The patient responded well to the 
treatment. The jugular venous pressure decreased, the 
swelling of the face and neck improved, and shortness 
of breath alleviated. The radiotherapy was discontinued 
despite clinical improvement because the evaluation 
of the chest x-ray revealed there were no objective 
signs of tumor shrinkage. We planned to do 3–4 cycles 
of chemotherapy with a platinum-based regimen to the 
patient and evaluate the serum alpha-fetoprotein serum 
level for eligibility for surgery. We did not have the chance 
to do the chemotherapy because the patient died two 
days after diagnosis was made. The patient’s family did 
not give us permission to do the autopsy.
DISCUSSION
We presented a case of yolk sac tumor in the 
anterior mediastinum of a 15 years old boy. Yolk sac 
tumor is a malignant GCT that occurs predominantly 
in male age 10 to 40 years and mostly found in gonadal 
sites [8]. However, rare cases of mediastinal yolk sac 
tumor in 2 years old girl and 66 years old women were 
also reported [8, 9]. Yolk sac tumor can also be found 
in extragonadal sites, most frequently in the anterior 
mediastinum. The patient was referred to Persaha-
batan Central General Hospital from a regional hos-
pital with superior vena cava syndrome. Previously, 
the patient presented with progressive dyspnea over 
2 weeks before superior vena cava syndrome deve-
loped. Patients with mediastinal GCTs usually present 
with dyspnea (25%), chest pain (23%), cough (17%), 
followed by fever (13%), weight loss (11%), vena cava 
superior syndrome (6%), fatigue/weakness (6%), and 
pain at other location except the chest (5%). Less 
frequent symptoms were chest wall or cervical mass 
(2%), and hemoptysis, hoarseness, nausea, or dys-
phagia (1% each) [3].
The computed tomography scan revealed the bulky 
mass with cystic component infiltrating to the right 
atrium. Echocardiography confirmed the findings and 
revealed pericardial effusion. These findings suggest 
cardiac involvement. Yolk sac tumor is very aggres-
sive, includes locally advanced and metastatic tumors 
at diagnosis [10, 11]. Several articles reported cases 
of yolk sac tumor (gonadal and extragonadal sites) 
with cardiac metastases [12–15]. To our knowledge, 
direct spread of mediastinal GCTs to the heart has 
never been reported before so this case is the first case 
such involvement has ever been reported.
The tumor can spread to the heart by four mecha-
nisms: (1) direct extension, (2) through the blood-
stream, (3) through the lymphatic system, (4) intra-
cavitary diffusion through either superior vena cava 
or pulmonary veins. The clinical findings of cardiac 
involvement in cancer are highly variable. Most fre-
quently, cardiac involvement goes unrecognized 
and only diagnosed until after death. The findings 
of cardiac involvement in our patient were found ac-
cidentally by computed tomography scan and echo-
cardiography [15].
Symptoms caused by cardiac involvement in can-
cer depend on the location of the tumor. Focal lesion 
secondary to the myocardium probably does not 
produce any symptoms. Pericardial involvement can 
produce increasing shortness of breath, hypotension, 
tachycardia, and clinical findings of cardiac tam-
ponade. Pericardial effusion is often the first clinical 
manifestation of pericardial involvement. In our patient, 
pericardial effusion is evident in ECG which showed low 
QRS voltage and appeared on echocardiography. If the 
tumor infiltrates the wall of the heart it may produce 
arrhythmias, conduction disturbances, and complete 
atrioventricular blocks. Ventricular involvement may 
cause heart failure due to systolic or diastolic dysfunc-
tion. Left atrial involvement may cause thrombi that 
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facilitate distant metastasis and cause an ischemic 
lesion in the systemic arterial system. Right atrial in-
volvement may cause thrombi that cause pulmonary 
emboli to the lung [15].
Our patient had increased serum alpha-fetoprotein 
and normal human chorionic gonadotropin level. 
These findings correspond with the nature of yolk 
sac tumor. Alpha-fetoprotein has been found in the 
serum, in the cytoplasm of the tumor cells, and in the 
eosinophilic globules by the immunohistochemical 
techniques in yolk sac tumors [10]. Alpha-fetoprotein 
is also used as a marker for evaluation of treatment and 
as a prognostic marker for the tumor [2–16].
Our patient came with superior vena cava syn-
drome so we performed radiotherapy to the tumor 
location to release compression of the tumor to the 
superior vena cava. The radiotherapy was discon-
tinued despite clinical improvement because there 
was no evident of objective shrinkage of the tumor. 
The mediastinal yolk sac tumor diagnosis was made 
after we performed core needle biopsy. Unfortunately, 
the patient died two days after diagnosis and we did 
not have the chance to administered chemotherapy. 
Current therapy of poor prognosis non-seminoma 
GCTs based on European Germ Cell Cancer Consen-
sus Group (EGCCCG) are 4 cycles of PEB (cisplatin, 
etoposide, and bleomycin) chemotherapy followed 
by evaluation of the tumor markers. Resection of the 
residual tumor can be done if the marker is normal-
ized and the tumor is resectable. If the tumor marker 
is elevated but reached a plateau level, follow-up is in-
dicated in 4–12 weeks. If there is no increase in tumor 
marker level, resection can be performed. However, 
if there is an increase in tumor marker level, salvage 
chemotherapy is indicated [16]. Primary mediastinal 
yolk sac tumor is classified as poor prognosis by the 
International Germ Cell Cancer Collaborative Group 
(IGCCCG) with the 5-year survival of 50% [7].
In another case report, it is showed that pre-op-
erative chemotherapy of PEB, followed by complete 
excision of all residual anterior mediastinal mass 
resulted in complete response for 5 years [5]. In our 
case, however, the patient presented with swelling 
of his face and neck and severe respiratory distress 
in the last one week that represent superior vena cava 
syndrome. Moreover, the tumor has already infiltrated 
the heart in our patient. This deteriorating condition 
did not allow us to start the chemotherapy, instead, 
radiotherapy was considered the appropriate options 
to relieve the symptoms at that moment.
In conclusion, primary mediastinal yolk sac tumor 
is an aggressive tumor that often invades and infiltrates 
surrounding structures and metastasis. We presented 
a unique case in which the tumor invaded the heart 
and formed mass inside the right atrium. The patient 
initially responded to the radiotherapy but then his 
condition declined rapidly due to his severe vena cave 
superior syndrome. In our case, we did not have the 
chance to do the chemotherapy treatment. Early diag-
nosis and treatment are important in the management 
of malignant GCTs. However, the prognosis of primary 
mediastinal yolk sac tumor is poor and further research 
is needed to find the best treatment modality and regi-
men for the tumor.
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